LOS ANGELES--(BUSINESS WIRE)-- CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company specializing in oncology, today announced interim study results that showed its doxorubicin prodrug INNO-206 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback